Inclusion Criteria:

   - Age >18 years

   - Providing written informed consent

   - Subjects with intermediate likelihood of obstructive CAD with an Updated
   Diamond-Forrester (UDF) risk score 20-80% with symptomatic, suspected CAD who:

   - In Cohort 1A & 2A only are scheduled to undergo initial clinically-indicated
   non-invasive coronary evaluation, and have not undergone non-invasive coronary
   evaluation, including exercise tolerance testing, stress echocardiography, SPECT or
   MRI, or cCTA, within the past 90 days OR ICA at any time; or

   - In Cohort 1B & 2B only have been referred to invasive coronary angiography (ICA) and
   have not undergone ICA within the past 90 days

   - Ability to undergo cCTA

Exclusion Criteria:

   - Suspicion of acute coronary syndrome. Subjects experiencing unstable angina are not
   excluded where clinical documentation has ruled out a myocardial infarction.

   - Prior, clinically documented myocardial infarction

   - PCI prior to first test

   - CABG prior to first test

   - Contraindications for cCTA such as:

   - Presence of pacemaker or internal defibrillator leads

   - Atrial Fibrillation

   - Known anaphylactic allergy to iodinated contrast

   - Pregnancy or unknown pregnancy status in women of childbearing potential

   - Body mass index >35 kg/m2

   - Contraindication to acute beta blockade

   - Contraindication to acute sublingual nitrate administration

   - Prosthetic heart valve

   - Contraindications to FFRCT

   - Complex Congenital Heart disease other than anomalous coronary origins alone

   - Ventricular septal defect with known Qp/Qs>1.4

   - Requiring an emergent procedure within 48 hours of presentation

   - Evidence of active clinical instability, including cardiogenic shock, unstable blood
   pressure with systolic blood pressure <90 mmHg, or NYHA Grade III or IV congestive
   heart failure or acute pulmonary edema

   - Any active, serious, life-threatening disease with a life expectancy of less than 2
   years

   - Inability to comply with study follow-up requirements

   - Current participation in any other clinical trial involving an investigational device
   or dictating care pathways at the time of enrollment.